Navigation Links
Experimental Chemical Helps Blind Mice See
Date:7/25/2012

WEDNESDAY, July 25 (HealthDay News) -- A novel chemical temporarily restored some vision to blind mice, and this success may eventually lead to a treatment to help people with degenerative blindness see again, according to a new study.

Those who could benefit include people with retinitis pigmentosa and age-related macular degeneration (AMD). Retinitis pigmentosa is a genetic disease that is the most common inherited form of blindness, while AMD is the most common cause of acquired blindness in the developed world.

In both diseases, light sensitive cells in the retina called rods and cones die and leave the eye without functioning photoreceptors.

The mice used in this study had genetic mutations that made their rods and cones die within months of birth. Injections of the chemical AAQ into the eyes of the blind mice temporarily restored their light sensitivity, according to the study published in the July 26 issue of the journal Neuron.

AAQ makes the remaining, normally "blind" cells in the retina sensitive to light, lead researcher Richard Kramer, a professor of molecular and cell biology at the University of California, Berkeley, explained in a university news release.

This approach "offers real hope to patients with retinal degeneration," study co-author Dr. Russell Van Gelder, chair of the ophthalmology department at the University of Washington in Seattle, said in the news release.

"We still need to show that these compounds are safe and will work in people the way they work in mice, but these results demonstrate that this class of compound restores light sensitivity to retinas blind from genetic disease," he added.

The researchers noted that the chemical eventually wears off, which may make it a safer alternative to other experimental methods for restoring sight, such as gene or stem cell therapies, which permanently change the retina. Chemical treatment is also less invasive than implanting light-sensitive chips in the eye, the researchers said.

"The advantage of this approach is that it is a simple chemical, which means that you can change the dosage, you can use it in combination with other therapies, or you can discontinue the therapy if you don't like the results. As improved chemicals become available, you could offer them to patients. You can't do that when you surgically implant a chip or after you genetically modify somebody," Kramer explained.

However, experts note that while studies involving animals can be useful, they frequently fail to produce similar results in humans.

The research was supported by the U.S. National Institutes of Health's National Eye Institute and Research to Prevent Blindness.

More information

The U.S. National Eye Institute has more about age-related macular degeneration.

-- Robert Preidt

SOURCE: University of California, Berkeley, news release, July 25, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental drug may extend therapeutic window for stroke
2. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
3. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
4. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
5. Experimental drug improves muscle strength among male cancer patients
6. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
7. Experimental Drug Eases Autistic Behaviors in Mice
8. Experimental Gel May Help Those With Advanced Parkinsons
9. Experimental Pill for Multiple Sclerosis Shows Promise
10. Experimental Chemo Combo for Colon Cancer Disappoints
11. American Chemical Societys highest honor to Peter Stang
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... the organization behind the New England Journal of Medicine and NEJM Journal Watch, ... Knowledge+ Pediatrics Board Review was created by a panel of pediatricians from leading ...
(Date:3/27/2017)... ... 27, 2017 , ... Osteitis pubis may be commonplace and ... it occurs when the muscles around the pelvis become inflamed. Over time, untreated ... torso, as well as accompanying tenderness and weakness. Without proper intervention, it can ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
(Date:3/27/2017)... ... 27, 2017 , ... Golden Triangle Emergency Center will be ... 3rd to commemorate the two-year anniversary of the facility. The event will feature ... great years while also familiarizing themselves with the facility. , In the two ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
(Date:3/27/2017)...  Twist Bioscience, a company accelerating science and innovation ... raised an additional $33 million. To date, Twist Bioscience ... "It is an exciting time to be leading ... to deliver industry-leading gene volume to our customers, enabling ... Leproust, Ph.D., CEO of Twist Bioscience. "We welcome the ...
(Date:3/27/2017)... , March 27, 2017   Genprex, Inc. , a ... Julien Pham , MD, the Company,s Chief Operating Officer, is ... conferences. Sachs 5th Annual Cancer BioPartnering & Investment ... New York, NY ... BioCentury 24th Annual Future Leaders in Biotech ...
Breaking Medicine Technology: